Blue Fin Capital Inc. decreased its stake in Bristol-Myers Squibb Company (NYSE:BMY) by 0.1% during the first quarter, according to its most recent disclosure with the SEC. The institutional investor owned 18,630 shares of the biopharmaceutical company’s stock after selling 25 shares during the period. Blue Fin Capital Inc.’s holdings in Bristol-Myers Squibb were worth $1,013,000 as of its most recent SEC filing.

Other large investors have also added to or reduced their stakes in the company. Sequoia Financial Advisors LLC boosted its stake in Bristol-Myers Squibb by 13.2% in the first quarter. Sequoia Financial Advisors LLC now owns 7,075 shares of the biopharmaceutical company’s stock valued at $385,000 after buying an additional 826 shares in the last quarter. Stoneridge Investment Partners LLC boosted its stake in shares of Bristol-Myers Squibb by 884.4% in the first quarter. Stoneridge Investment Partners LLC now owns 60,726 shares of the biopharmaceutical company’s stock worth $3,302,000 after buying an additional 54,557 shares during the period. GFS Advisors LLC purchased a new stake in shares of Bristol-Myers Squibb during the first quarter worth approximately $274,000. Willingdon Wealth Management boosted its stake in shares of Bristol-Myers Squibb by 83.7% in the first quarter. Willingdon Wealth Management now owns 121,618 shares of the biopharmaceutical company’s stock worth $6,614,000 after buying an additional 55,420 shares during the period. Finally, Usca Ria LLC boosted its stake in shares of Bristol-Myers Squibb by 21.7% in the first quarter. Usca Ria LLC now owns 49,523 shares of the biopharmaceutical company’s stock worth $2,693,000 after buying an additional 8,814 shares during the period. 69.56% of the stock is owned by institutional investors and hedge funds.

Bristol-Myers Squibb Company (BMY) traded up 0.81% on Friday, reaching $55.95. The company’s stock had a trading volume of 4,150,120 shares. Bristol-Myers Squibb Company has a one year low of $46.01 and a one year high of $75.62. The company has a market capitalization of $91.75 billion, a PE ratio of 20.43 and a beta of 1.17. The firm has a 50-day moving average of $55.55 and a 200-day moving average of $54.50. Bristol-Myers Squibb also was the recipient of unusually large options trading activity on Thursday. Stock traders acquired 781 put options on the stock. This represents an increase of approximately 117% compared to the typical volume of 360 put options.

Bristol-Myers Squibb (NYSE:BMY) last released its quarterly earnings results on Thursday, July 27th. The biopharmaceutical company reported $0.74 earnings per share for the quarter, topping the consensus estimate of $0.73 by $0.01. Bristol-Myers Squibb had a net margin of 22.66% and a return on equity of 32.33%. The firm had revenue of $5.14 billion during the quarter, compared to the consensus estimate of $5.09 billion. During the same quarter in the prior year, the firm earned $0.69 EPS. The company’s revenue for the quarter was up 5.6% on a year-over-year basis. Analysts predict that Bristol-Myers Squibb Company will post $2.97 EPS for the current year.

The business also recently declared a quarterly dividend, which was paid on Tuesday, August 1st. Investors of record on Friday, July 7th were given a dividend of $0.39 per share. The ex-dividend date of this dividend was Wednesday, July 5th. This represents a $1.56 annualized dividend and a dividend yield of 2.79%. Bristol-Myers Squibb’s dividend payout ratio (DPR) is presently 56.73%.

ILLEGAL ACTIVITY NOTICE: This report was first published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this report on another domain, it was illegally copied and republished in violation of US and international trademark & copyright legislation. The correct version of this report can be viewed at https://www.thecerbatgem.com/2017/08/04/bristol-myers-squibb-company-nysebmy-position-decreased-by-blue-fin-capital-inc-updated-updated-updated.html.

A number of analysts recently commented on BMY shares. BMO Capital Markets lowered Bristol-Myers Squibb from a “market perform” rating to an “underperform” rating and set a $47.00 price target on the stock. in a report on Wednesday, May 3rd. Robert W. Baird started coverage on Bristol-Myers Squibb in a report on Tuesday, April 25th. They set an “outperform” rating on the stock. Jefferies Group LLC reiterated a “buy” rating and set a $64.00 price target on shares of Bristol-Myers Squibb in a report on Monday, June 5th. Vetr upgraded Bristol-Myers Squibb from a “buy” rating to a “strong-buy” rating and set a $58.88 target price on the stock in a research note on Monday, June 5th. Finally, BidaskClub lowered Bristol-Myers Squibb from a “buy” rating to a “hold” rating in a research note on Monday, July 3rd. Two analysts have rated the stock with a sell rating, eleven have assigned a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the stock. The stock has a consensus rating of “Hold” and an average target price of $63.32.

In related news, Director Theodore R. Samuels II purchased 6,000 shares of Bristol-Myers Squibb stock in a transaction that occurred on Wednesday, August 2nd. The stock was purchased at an average price of $55.94 per share, for a total transaction of $335,640.00. Following the transaction, the director now directly owns 18,000 shares in the company, valued at $1,006,920. The acquisition was disclosed in a document filed with the SEC, which is available at this link. 0.23% of the stock is owned by corporate insiders.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Stock Ratings for Bristol-Myers Squibb Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb Company and related stocks with our FREE daily email newsletter.